Yu Z, Yang Q, Sun J, Zhen J
Department of Breast Surgery, the Second Affiliated Hospital of Shandong University, Ji'nan, Shandong Province, People's Republic of China.
Exp Oncol. 2007 Sep;29(3):192-6.
The fluoropyrimidine drug fluorouracil (FU) is one of the most frequently prescribed chemotherapeutic drugs for the curative and palliative treatment of various cancer patients. The identification of biological factors associated with tumors either responsiveness or resistance to FU chemotherapy, including FU, is increasingly being recognized as an important field of clinical cancer research.
to analyze the relationship between intra-tumoral dihydropyrimidine dehydrogenase (DPD) level and FU chemosensitivity, as DPD is the initial and rate-limiting enzyme in the catabolism of FU.
The histoculture drug response assay (HDRA) was performed for 54 patients. DPD expression was examined in 81 tumor samples from breast cancer patients received two cycles of FU-based primary chemotherapy before operation.
We found that intra-tumoral DPD enzyme activity was inversely correlated with FU cytotoxicity. We also revealed that low DPD expression was correlated with clinical response to FU-based primary chemotherapy.
Our study indicated that DPD is a promising molecular maker for identifying tumor cells sensitivity in breast cancer patients receiving FU-based chemotherapy.
氟嘧啶类药物氟尿嘧啶（FU）是治疗各类癌症患者最常用的化疗药物之一。识别与肿瘤对FU化疗的反应性或耐药性相关的生物学因素，包括FU，正日益被视为临床癌症研究的一个重要领域。
分析肿瘤内二氢嘧啶脱氢酶（DPD）水平与FU化疗敏感性之间的关系，因为DPD是FU分解代谢的起始和限速酶。
对54例患者进行组织培养药物反应试验（HDRA）。检测了81例接受两周期术前基于FU的原发性化疗的乳腺癌患者肿瘤样本中的DPD表达。
我们发现肿瘤内DPD酶活性与FU细胞毒性呈负相关。我们还发现低DPD表达与基于FU的原发性化疗的临床反应相关。
我们的研究表明，DPD是识别接受基于FU化疗的乳腺癌患者肿瘤细胞敏感性的一个有前景的分子标志物。
